An early stage fund with a China-based parent investment firm built its own science park near Shanghai to help companies expand successfully into the China market. The firm invests in 3 to 5 deals a year at seed stage. The fund has particular success in fostering joint development initiatives between U.S. and China-based companies. The firm invests in companies based in the U.S., China, or Europe.
The fund invests in early-stage therapeutics, medical devices, diagnostics, and healthcare IT. The firm is particularly interested in early-stage therapeutic companies, and their second priority would be diagnostics. The firm has expertise in the oncology field, and the firm is open to looking at orphan diseases. In addition, the firm is also open to lab equipment and drug development enabling technology.
The fund supports companies who have an international business model with desires to expand into the US, China, and/or Europe.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment